This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Lymphomas Non-Hodgkin's B-Cell or Relapse
and you are
between 18 and 70
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

In this single-center, open-label, no control, prospective clinical trial, a total of 10 relapsed or refractory CD19 positive B-cell Non-Hodgkin Lymphoma (NHL) patients will be enrolled.CD19 CAR T cells(total dose of 2×10^6/kg-1×10^7/kg) will be intravenously infused to patient in a three-day split-dose regimen: 10% on day 0, 30% on day 1 and 60% on day 2. The purpose of current study is to determine the clinical efficacy and safety of CD19 CAR T cells in patients with relapsed or refractory CD19 positive B-cell lymphoma.

Provided treatments

  • Biological: CD19 CAR T cells

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT03029338. The sponsor of the trial is Institute of Hematology & Blood Diseases Hospital and it is looking for 20 volunteers for the current phase.
Official trial title:
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma